Genome analysis and prevalence of SARS-CoV-2 Indonesian variants and the correlation with the outbreak timeline
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone multiple mutations, leading to the development of various variants.
Objective: To identify the genetic mutations associated with the transmission and virulence of SARS-CoV-2 variants in Indonesia and to examine their correlation with the outbreak timeline.
Methods: We analyzed whole genome sequences of SARS-CoV-2 wild type and variants isolated from Indonesian samples, sourced from GenBank and the GISAID EpiCoV database. The spike glycoprotein gene sequences were examined using the BLAST to identify nucleotide and amino acid changes. Additionally, we investigated the prevalence of these variants and their submission timelines on the GISAID database, correlating them with the outbreak timeline.
Results: Our analysis identified nine amino acid changes in the alpha, beta, and delta variants, and three in the gamma variant, compared to the wild type. A correlation between the submission timelines of SARS-CoV-2 variants and the outbreak timeline indicated that the delta variant (B.1.617.2) likely contributed to the surge in COVID-19 cases from July to September 2021.
Conclusion: Mutations were detected in each variant, emerging at distinct times, and are likely to influence transmission rates and virulence.
References
Mayo Clinic (2021) Coronavirus disease 2019 (COVID-19) - Symptoms and causes. https://www.mayoclinic.org/diseases-conditions/coronavirus/symptoms-causes/syc-20479963. Accessed date: December 2021.
WHO (2020) Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Accessed date: December 2021.
Zhang L, Jackson CB, Mou H et al. (2020) SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nature Communications 11 (1): 6013. https://doi.org/10.1038/s41467-020-19808-4
WHO (2021) WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int. Accessed date: December 2021.
Mathieu E, Ritchie H, Rodés-Guirao L et al. (2020) Coronavirus Pandemic (COVID-19). https://ourworldindata.org/coronavirus-data. Accessed date: December 2021.
Lu R, Zhao X, Li J et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet 395 (10224): 565-574. https://doi.org/10.1016/S0140-6736(20)30251-8
Huang Y, Yang C, Xu X et al. (2020) Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica 41 (9): 1141-1149. https://doi.org/10.1038/s41401-020-0485-4
Chan JF-W, Kok K-H, Zhu Z et al. (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections 9 (1): 221-236. https://doi.org/10.1080/22221751.2020.1719902
Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses: methods and protocols 1-23. doi: 10.1007/978-1-4939-2438-7_1.https://doi.org/10.1007/978-1-4939-2438-7_1
Loewe L (2008) Genetic mutation. Nature education 1 (1): 113.
Wei-Haas M (2021) The coronavirus is mutating-but what determines how quickly? https://www.nationalgeographic.com/science/article/the-coronavirus-is-mutating-but-what-determines-how-quickly. Accessed date: December 2021.
Duffy S (2018) Why are RNA virus mutation rates so damn high? PLoS biology 16 (8): e3000003. https://doi.org/10.1371/journal.pbio.3000003
Sanjuán R, Domingo-Calap P (2016) Mechanisms of viral mutation. Cellular and molecular life sciences 73 4433-4448. https://doi.org/10.1007/s00018-016-2299-6
Callaway E (2020) The coronavirus is mutating - does it matter? Nature 585 (7824): 174-177. https://doi.org/10.1038/d41586-020-02544-6
Centers for Disease Control and Prevention (2021) SARS-CoV-2 Variant Classifications and Definitions. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html.
WHO (2020) Tracking SARS-CoV-2 variants. https://www.who.int/emergencies/emergency-health-kits/trauma-emergency-surgery-kit-who-tesk-2019/tracking-SARS-CoV-2-variants. Accessed date: December 2021.
ECDC (2021) SARS-CoV-2 variants of concern as of 3 December 2021. https://www.ecdc.europa.eu/en/covid-19/variants-concern. Accessed date: December 2021.
World Health Organization (2021) "COVID-19 Weekly Epidemiological Update - 28 September 2021." World Health Organization.
Ministry of Health Republic of Indonesia (2021) "COVID-19 Situation Report - Indonesia." Ministry of Health Republic of Indonesia.
Indonesia Health Metrics and Evaluation (2021) "Impact of COVID-19 on Indonesia: Trends and Insights." Indonesia Health Metrics and Evaluation.
Wu F, Zhao S, Yu B et al. (2020) A novel coronavirus associated with human respiratory disease in China. Nature 579 (7798): 265-269. https://doi.org/10.1038/s41586-020-2008-3
Wood AR, Esko T, Yang J, et al (2014) Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet 46(11):1173-86. https://doi.org/10.1038/ng.3097
UpToDate (2021) SARS-CoV-2 Variants of Concern. https://www.uptodate.com/contents/image?imageKey=ID%2F131216. Accessed date: December 2021.
Motozono C, Toyoda M, Zahradnik J et al. (2021) An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. BioRxiv 2004-2021. https://doi.org/10.1101/2021.04.02.438288
Harvey WT, Carabelli AM, Jackson B et al. (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology 19 (7): 409-424. https://doi.org/10.1038/s41579-021-00573-0
Collier DA, De Marco A, Ferreira IATM et al. (2021) Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies. Nature 593 (7857): 136-141. https://doi.org/10.1038/s41586-021-03412-7
Wibmer CK, Ayres F, Hermanus T et al. (2021) SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma. Nature medicine 27 (4): 622-625. https://doi.org/10.1038/s41591-021-01285-x
Timmers LFSM, Peixoto JV, Ducati RG et al. (2021) SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions. Scientific reports 11 (1): 11998. https://doi.org/10.1038/s41598-021-91585-6
Liu Y, Arase N, Kishikawa J et al. (2021) The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines. BioRxiv 2008-2021. https://doi.org/10.1101/2021.08.22.457114
Kannan SR, Spratt AN, Cohen AR et al. (2021) Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. Journal of autoimmunity 124 102715. https://doi.org/10.1016/j.jaut.2021.102715
Cherian S, Potdar V, Jadhav S et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv 2021: 2021.04. 22.440932. Published online May. https://doi.org/10.1101/2021.04.22.440932
McCallum M, Bassi J, De Marco A et al. (2021) SARS-CoV-2 immune evasion by the B. 1.427/B. 1.429 variant of concern. Science 373 (6555): 648-654. https://doi.org/10.1101/2021.03.31.437925
Planas D, Veyer D, Baidaliuk A et al. (2021) Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596 (7871): 276-280. https://doi.org/10.1038/s41586-021-03777-9
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
